Psychopharmacology

, Volume 186, Issue 2, pp 209–217

Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats

  • Han-Ting Zhang
  • Yu Zhao
  • Ying Huang
  • Chengjun Deng
  • Allen T. Hopper
  • Michael De Vivo
  • Gregory M. Rose
  • James M. O’Donnell
Original Investigation

Abstract

Rationale

Phosphodiesterase-4 (PDE4) has two conformation states based on rolipram binding, the high-affinity rolipram binding state (HARBS) and the low-affinity rolipram binding state (LARBS); their functions remain to be fully explained.

Objective

Experiments were carried out to determine the roles of the HARBS and LARBS in the mediation of antidepressant-like effects on behavior.

Materials and methods

Two animal models sensitive to antidepressant drugs, the forced-swim test (FST), and the differential-reinforcement-of-low-rate (DRL) 72-s operant schedule, were used to examine the antidepressant-like effects of rolipram, CDP840, and piclamilast, PDE4 inhibitors that interact differentially with the HARBS and LARBS, and MEM1018 and MEM1091, two novel PDE4 inhibitors. Drug discrimination vs rolipram and rolipram competition binding assays also were carried out.

Results

In the FST, rolipram and piclamilast, both at 0.1 mg/kg, produced an antidepressant-like effect, i.e., reduced immobility and increased swimming, whereas, 1 mg/kg of CDP840 or 0.5 mg/kg of MEM1018 or MEM1091 was required to produce a similar effect. Consistent with this, only rolipram and piclamilast produced antidepressant-like effects in rats under the DRL schedule of reinforcement, as evidenced by decreased response rates and increased reinforcement rates. In addition, in rats trained to discriminate rolipram from its vehicle, only rolipram and piclamilast substituted. Finally, [3H]rolipram and [3H]piclamilast binding analysis revealed that CDP840 and the two novel PDE4 inhibitors MEM1018 and MEM1091 exhibited a lower affinity for the HARBS than did rolipram.

Conclusion

These results suggest that the HARBS of PDE4 is the primary conformation important for antidepressant-like effects on behavior.

Keywords

Antidepressant Drug discrimination Behavior Phosphodiesterase PDE4 inhibitor Forced-swim DRL Rolipram binding site 

References

  1. Asanuma M, Nishibayashi S, Iwata E, Kondo Y, Nakanishi T, Vargas MG, Ogawa N (1996) Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res Mol Brain Res 41:210–215PubMedCrossRefGoogle Scholar
  2. Brucato FH, Hopper AT, Cook KQ, Chanas B, Deng CJ, Fiorino DF (2005) PDE4 inhibitor affinity at the high affinity rolipram binding site (HARBS) predicts efficacy in the rat pup ultrasonic vocalization model. Program No. 1024.12. Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, District of ColumbiaGoogle Scholar
  3. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108PubMedCrossRefGoogle Scholar
  4. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493–5496PubMedCrossRefGoogle Scholar
  5. Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW, Hellewell PG (1999) A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 126:1863–1871PubMedCrossRefGoogle Scholar
  6. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW (1996) Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120–125PubMedCrossRefGoogle Scholar
  7. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1–18PubMedCrossRefGoogle Scholar
  8. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891–899PubMedGoogle Scholar
  9. Kaulen P, Bruning G, Schneider HH, Sarter M, Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229–245PubMedCrossRefGoogle Scholar
  10. Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ (2001) Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization. Drug Metab Dispos 29:232–241PubMedGoogle Scholar
  11. Makhay MM, Houslay MD, O’Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology (Berl) 158:297–304CrossRefGoogle Scholar
  12. Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, Nakagawa H (1989) Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants. Nippon Yakurigaku Zasshi 94:81–89PubMedGoogle Scholar
  13. O’Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168–1178PubMedGoogle Scholar
  14. O’Donnell JM, Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185–192PubMedCrossRefGoogle Scholar
  15. O’Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158–163PubMedCrossRefGoogle Scholar
  16. O’Donnell JM, Wolfe BB, Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640–647PubMedGoogle Scholar
  17. Ortmann R, Meisburger JG (1986) Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berl) 89:273–277CrossRefGoogle Scholar
  18. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147:162–167CrossRefGoogle Scholar
  19. Renau TE (2004) The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr Opin Investig Drugs 5:34–39PubMedGoogle Scholar
  20. Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136:190–197CrossRefGoogle Scholar
  21. Schmiechen R, Schneider HH, Wachtel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacol Ser (Berl) 102:17–20CrossRefGoogle Scholar
  22. Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105–115PubMedCrossRefGoogle Scholar
  23. Soto FJ, Hanania NA (2005) Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 11:129–134PubMedGoogle Scholar
  24. Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227–236PubMedCrossRefGoogle Scholar
  25. Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol 121:743–750PubMedCrossRefGoogle Scholar
  26. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198–204PubMedCrossRefGoogle Scholar
  27. Zhang HT, Frith SA, Wilkins J, O’Donnell JM (2001) Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl) 159:89–97CrossRefGoogle Scholar
  28. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O’Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587–595PubMedGoogle Scholar
  29. Zhang HT, Huang Y, O’Donnell JM (2003) Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats. Psychopharmacology (Berl) 170:102–107CrossRefGoogle Scholar
  30. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by Infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432–1439PubMedCrossRefGoogle Scholar
  31. Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O’Donnell JM (2005a) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 179:613–619CrossRefGoogle Scholar
  32. Zhang HT, Huang Y, Mishler K, Roerig SC, O’Donnell JM (2005b) Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats. Psychopharmacology (Berl) 182:104–115CrossRefGoogle Scholar
  33. Zhao Y, Zhang HT, O’Donnell JM (2003a) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 305:565–572PubMedCrossRefGoogle Scholar
  34. Zhao Y, Zhang HT, O’Donnell JM (2003b) Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307:246–253PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Han-Ting Zhang
    • 1
  • Yu Zhao
    • 2
  • Ying Huang
    • 1
  • Chengjun Deng
    • 3
  • Allen T. Hopper
    • 3
  • Michael De Vivo
    • 3
  • Gregory M. Rose
    • 3
  • James M. O’Donnell
    • 1
  1. 1.Departments of Behavioral Medicine & Psychiatry and Neurobiology & AnatomyWest Virginia University Health Sciences CenterMorgantownUSA
  2. 2.Molecular and Integrative Neuroscience DepartmentThe Scripps Research InstituteLa JollaUSA
  3. 3.Memory Pharmaceuticals Corp.MontvaleUSA

Personalised recommendations